Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Hepatology. 2021 Jun 15;74(3):1371–1383. doi: 10.1002/hep.31803

Figure 3. Clinical validation of the risk-stratification model in patients with ICC.

Figure 3.

A) The risk-stratification model, which combines the transcriptomic panel and clinical risk factors, outperformed detection accuracy of the transcriptomic panel or risk factors alone in tissue specimens from validation cohort patients (AUC = 0.89). B–C) Forest plot with HRs of clinicopathological variables, transcriptomic panel, and risk-stratification model in univariate (B) and multivariate (C) Cox proportional hazard regression analysis in validation cohort patients. D) A comparison of RFS between high and low-risk group estimated by the risk-stratification model in the validation cohort (left panel). The risk-stratification model would have led to the 5-year recurrence rate of 24% patients with low-risk and 85% patients with high-risk ICC (right panel).